Advertisement

Topics

Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options

07:48 EDT 11 Aug 2017 | FinanzNachrichten

LONDON (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) Friday said that it has retained all rights to inotersen and IONIS-FB-Lrx. GlaxoSmithKline Plc (GSK.L, GSK) declined its options on both drugs...

Original Article: Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options

NEXT ARTICLE

More From BioPortfolio on "Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options"

Quick Search
Advertisement
 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...